We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Rakuten Aspyrian Inc. (formerly known as Aspyrian Therapeutics) raised $150mm through its Series C round led by company chairman and CEO of Rakuten Inc., Hiroshi Mikitani. The company is developing photoimmunotherapies for cancer and will use the Series C funds to advance lead compound ASP1929 into Phase III trials by the end of 2018 for recurrent head and neck squamous cell carcinomas. Funds will also go towards manufacturing scale-up for future commercialization of the candidate, build-up of commercial operations to support launching ASP1929 in the US, Europe, and Japan, and potential expansion of research for the candidate in other cancers.
Deal Industry
Pharmaceuticals
Biotechnology
Large Molecule
Antibodies
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?